Clinical trials: Neonatal Stroke
Stroke, Ischemic, Genetic Disease
CUHK Stroke Biobank
The purpose of the study are: 1. To make quality, characterized samples and related data available for future studies, including Genome Wide Association Studies (GWAS), genomics, and biomarker research; 2.
- Conditions
- Stroke, Ischemic, Genetic Disease, Atherosclerosis, Cerebral
- Trial name
- NCT03291392
- Testing
- Gene expression or biomarkers exploration
- Where
- Hong Kong
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Sickle Cell Disease, Stroke
The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria
Sickle Cell Anemia (SCA) occurs in 300,000 newborns per year in the world, with 150,000 affected births in Nigeria, alone. With improvement in survival for children with SCA in both high- and low-resource countries, neurological…
- Conditions
- Sickle Cell Disease, Stroke, Neurologic Manifestations, Neurological Morbidity
- Trial name
- NCT04800809
- Testing
- This study does not entail offering any intervention; all data collected will be based on standard of care.
- Where
- 3 sites in United States, Nigeria
- Volunteers
- 350 people
- Sponsor
- Vanderbilt University Medical Center
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Ischemic Stroke
Effect of EA Combined With NGF on Limb Function in Convalescent Patients With Ischemic Stroke
Most ischemic stroke patients are in recovery phase, often accompanied by motor impairment, but they lack effective treatment. The appearance of nerve growth factor (NGF) promotes the development of neuroprotective therapy, but…
- Trial name
- NCT05652751
- Testing
- nerve growth factor, physiological saline, EA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Cardiac Structure and Function in Patients with Cystic Fibrosis
In a prospective observational cohort study (n = 100), the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and cystic fibrosis genotype and severity and determine whether these…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis, Pulmonary, Cystic Fibrosis of Pancreas
- Trial name
- NCT06084468
- Where
- 2 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Herlev and Gentofte Hospital
Brain Tumor, Stroke, Acute
Safety and Feasibility of the Infinity Catheter for Radial Access
The main objective of this single arm study is to evaluate the safety and feasibility of the AXS Infinity LS (Stryker, Freemont, CA, USA) and AXS Infinity LS Plus (Stryker, Freemont, CA, USA) catheters during the transradial…
- Conditions
- Brain Tumor, Stroke, Acute, Brain Aneurysm, Intracranial Arteriovenous Malformations
- Trial name
- NCT04553549
- Testing
- Transradial approach
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Rutgers, The State University of New Jersey
Neurologic Diseases, Hemiparesis
NuroSleeve Powered Brace & Stimulation System to Restore Arm Function
The purpose of this study is to investigate if a person with weakness or paralysis in one or both arms, can use the NuroSleeve combined powered arm brace (orthosis) and muscle stimulation system to help restore movement in one…
- Conditions
- Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies
- Trial name
- NCT04798378
- Testing
- Neurosleeve
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Hemiplegic Cerebral Palsy, Perinatal Stroke
Robotic Rehabilitation and Brain Stimulation for Children With Hemiparetic Cerebral Palsy
This study evaluates the use of robotic rehabilitation with and without transcranial direct current stimulation (tDCS) to improve motor performance in children with hemiparetic cerebral palsy.
- Trial name
- RoboCP (NCT04233710)
- Testing
- Robot Rehabilitation + tDCS
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Blood Disease, Cerebrovascular Accident
Stroke Prevention in Sickle Cell Anemia (STOP 2)
To determine how long blood transfusions are needed for primary stroke prevention. Also, to determine the duration of risk associated with abnormal transcranial Doppler ultrasound (TCD) and to determine the specificity of the…
- Conditions
- Blood Disease, Cerebrovascular Accident, Anemia, Sickle Cell
- Trial name
- NCT00006182
- Testing
- Blood Transfusion
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cerebrovascular Accident, Fabry Disease
Vasodilation in Patients With Fabry's Disease
Fabry's disease a genetic disorder (X-linked recessive) due to the absence of the enzyme alpha-galactosidase A. The disease is characterized by abnormal collections of glycolipids in cells (histiocytes) within blood vessel walls…
- Conditions
- Cerebrovascular Accident, Fabry Disease, Healthy
- Trial name
- NCT00001774
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
A Phase 2b Study of Zagociguat in Patients With MELAS
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs.
- Trial name
- PRIZM (NCT06402123)
- Testing
- zagociguat 15mg, zagociguat 30mg
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 43 people
- Sponsor
- Tisento Therapeutics
Acute Ischemic Stroke
Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke
Stroke remains one of the leading causes of death and adult disability worldwide. Yet, currently, the only accepted treatment for acute ischemic stroke(AIS) is recanalization of occluded arteries.
- Trial name
- NCT03686163
- Testing
- Nerve Growth Factors, normal saline
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Jinling Hospital, China
Cryptogenic Stroke, Foramen Ovale, Patent
Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study
The aim of the ALFA ROMEO study is to better understand the association between cryptogenic stroke, PFO, PFO closure and AF.
- Conditions
- Cryptogenic Stroke, Foramen Ovale, Patent, Atrial Fibrillation
- Trial name
- ALFA-ROMEO (NCT04881578)
- Testing
- continuous cardiac monitoring before and after transcatheter PFO closure
- Where
- 6 sites in Switzerland
- Volunteers
- 200 people
- Sponsor
- Raban Jeger
Gangliosidoses, GM1 Gangliosidosis
Registry Gangliosidoses
The clinical project "Eight At One Stroke: Attention Gangliosidoses" represents a clinical registry for recording the clinical manifestation and the disease progression of gangliosidoses.
- Conditions
- Gangliosidoses, GM1 Gangliosidosis, Morquio B Disease, Sialidosis
- Trial name
- NCT04624789
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- SphinCS Lyso Gemeinnutzige UG (Haftungsbeschrankt)
Patent Foramen Ovale, Ischemic Stroke
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
- Conditions
- Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer
- Trial name
- HALTI (NCT04475510)
- Testing
- Antiplatelet treatment discontinuation
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Josep Rodes-Cabau
Sickle Cell Disease
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using immune- suppressive agents and low-dose…
- Trial name
- NCT01499888
- Testing
- Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Illinois Chicago
Stroke
Standardized Goal-Directed vs. Self-Directed Valsalva Maneuver for the Assessment of Patent Foramen Ovale
Ischemic stroke represents a major public health issue, leading to significant disabilities and deaths worldwide. When no clear cause for stroke is found following a comprehensive cardiovascular evaluation (no atrial…
- Trial name
- NCT06670781
- Testing
- Experimental: Intervention arm: Goal-Directed Valsalva maneuver, Control - standard of care: Self-Directed Valsalva maneuver
- Where
- 2 sites in Canada
- Volunteers
- 488 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cerebrovascular Accident, Post-polio Syndrome
Nomad P-KAFO Study
The goal of this clinical trial is to evaluate the impact of using the Nomad powered KAFO in people who have had a musculoskeletal or neurological injury that has affected their ability to walk.
- Conditions
- Cerebrovascular Accident, Post-polio Syndrome, Spinal Cord Injuries, Multiple Sclerosis
- Trial name
- NCT05644522
- Testing
- Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Shirley Ryan AbilityLab
Fabry Disease
Dosing Study of Replagal in Patients With Fabry Disease
This study will determine the safety and effectiveness of increasing Replagal infusions in certain patients with Fabry disease. Replagal is a genetically engineered form of Alpha-galactosidase A, an enzyme that normally breaks…
- Trial name
- NCT00068107
- Testing
- Replagal
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Sickle Cell Disease, Stroke
Stroke Prevention in Nigeria 2 Trial
The primary goal of this study is to complete a multicenter single-arm, type I hybrid trial to assess the effectiveness of hydroxyurea therapy for primary stroke prevention in high-risk children with sickle cell anemia (SCA)…
- Trial name
- SPRING-2 (NCT06526117)
- Testing
- Hydroxyurea
- Where
- 2 sites in Nigeria
- Volunteers
- 220 people
- Sponsor
- Vanderbilt University Medical Center